Leiter L.A.
550
Coauthors
16
Documentos
Volumen de publicaciones por año
Cargando gráfico
Año de publicación | Num. Publicaciones |
---|---|
2016 | 3 |
2018 | 2 |
2019 | 2 |
2020 | 3 |
2021 | 4 |
2022 | 2 |
Publicaciones por áreas de conocimiento
Cargando gráfico
Área de conocimiento | Num. Publicaciones |
---|---|
Medicina interna | 13 |
Enfermedad cardiovascular | 8 |
Diabetes | 7 |
Medicamento | 4 |
Cognición | 2 |
Neurología | 1 |
Publicaciones por áreas temáticas
Cargando gráfico
Área temática | Num. Publicaciones |
---|---|
Enfermedades | 14 |
Farmacología y terapéutica | 11 |
Medicina y salud | 8 |
Fisiología humana | 5 |
Salud y seguridad personal | 2 |
Problemas sociales y servicios a grupos | 1 |
Ginecología, obstetricia, pediatría, geriatría | 1 |
Medicina forense; incidencia de enfermedades | 1 |
Principales fuentes de datos
Origen | Num. Publicaciones |
---|---|
Scopus | 16 |
Google Scholar | 15 |
RRAAE | 0 |
Cargando gráfico
Coautores destacados por número de publicaciones
Coautor | Num. Publicaciones |
---|---|
PATRICIO LOPEZ -JARAMILLO | 16 |
Dagenais G.R. | 14 |
Keltai M. | 13 |
Avezum A.J. | 12 |
Jansky P. | 12 |
Pais P. | 10 |
DIaz R. | 10 |
Pogosova N. | 10 |
Rydén L.E. | 10 |
Basile J.N. | 10 |
Cargando gráfico
Top Keywords
Cargando gráfico
Publicaciones del autor
Effects of lipid-lowering and antihypertensive treatments in addition to healthy lifestyles in primary prevention: An analysis of the HOPE-3 trial
ArticleAbstract: Background-It is not clear whether the effects of lipid-lowering or antihypertensive medications arePalabras claves:Antihypertensive agent, statinAutores:Avezum A.J., Bogaty P.M., Bosch J.J., Dagenais G.R., Dehghan M., Held C., Jansky P., Jung H., Keltai M., Leiter L.A., Lonn E.M., PATRICIO LOPEZ -JARAMILLO, Toff W.D., Yusuf S.Fuentes:googlescopusDulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes: A post hoc analysis from the REWIND randomized trial
ArticleAbstract: Aim: To assess the occurrence of atrial fibrillation or atrial flutter (atrial arrhythmias [AA]) inPalabras claves:Atrial Fibrillation, atrial flutter, dulaglutide, glucagon-like peptide-1 receptor agonists, Type 2 DiabetesAutores:Avezum A.J., Basile J.N., C. Gerstein H., Conget I., Cushman W.C., Dagenais G.R., Hoover A., Jansky P., Lanas F.T., Leiter L.A., PATRICIO LOPEZ -JARAMILLO, Pogosova N., Probstfield J.L., Rao-Melacini P., Raubenheimer P.J., Rydén L.E., Sheu W.H.H., Temelkova-Kurktschiev T.Fuentes:googlescopusAntihypertensives and Statin Therapy for Primary Stroke Prevention: A Secondary Analysis of the HOPE-3 Tria
ArticleAbstract: Background and Purpose: The HOPE-3 trial (Heart Outcomes Prevention Evaluation-3) found that antihypPalabras claves:Blood pressure, candesartan, Cardiovascular disease, Lipoprotein, Primary Prevention, statinAutores:Avezum A.J., Bosch J.J., Chazova I.E., Dagenais G.R., Gao P., Hart R.G., Held C., Khunti K., Leiter L.A., Lewis B.S., Lonn E.M., Pais P., PATRICIO LOPEZ -JARAMILLO, Peters R.J.G., Reid C.M., Sliwa K., Toff W.D., Yusoff K., Yusuf S., Zhu J.Fuentes:googlescopusErectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial
ArticleAbstract: Background: Diabetes is a major risk factor for erectile dysfunction, however, the effect of GLP-1 rPalabras claves:Autores:Bajaj H.S., Basile J.N., Colhoun H.M., Conget I., Cushman W.C., Dagenais G.R., Franek E., Gerstein H.C., Hanefeld M., Keltai M., Lakshmanan M., Lanas F.T., Leiter L.A., PATRICIO LOPEZ -JARAMILLO, Pirags V., Pogosova N., Probstfield J.L., Rao-Melacini P., Raubenheimer P.J., Rydén L.E., Shaw J.E., Sheu W.H.H., Xavier D.Fuentes:googlescopusSimilar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin
ArticleAbstract: Objective : Recent European Guidelines for Diabetes, Pbkp_rediabetes and Cardiovascular Diseases intPalabras claves:Cardiovascular disease, GLP-1-based therapy, Metformin, Morbidity, MortalityAutores:Avezum A.J., Basile J.N., Colhoun H.M., Cushman W.C., Dagenais G.R., DIaz R., Dyal L., Ferrannini G., Gerstein H.C., Jansky P., Keltai M., Lakshmanan M., Lanas F.T., Leiter L.A., Mellbin L., Pais P., PATRICIO LOPEZ -JARAMILLO, PīrCrossed D Sign gs V., Pogosova N., Probstfield J.L., Raubenheimer P.J., Riddle M.C., Rydén L.E., Shaw J.E., Sheu W.H.H.Fuentes:googlescopus